Spots Global Cancer Trial Database for Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

Official Title: Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

Study ID: NCT00568490

Conditions

Head and Neck Cancers

Interventions

Tumor biopsy

Phlebotomy

Study Description

Brief Summary: The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Detailed Description: The endpoints of the study are 1. To validate the prognostic significance of OPN in H\&N and lung cancer patients and to monitor its level during active therapy and follow up for cancer surveillance. 2. To identify a gene and protein signature for hypoxia in H\&N and lung cancer patients.